Results 11 to 20 of about 55,357 (215)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Biomolecules & Biomedicine, 2022
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin , Denizcan Güven , Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan , Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker , Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç , Abdullah Sakin , Haci Mehmet Türk, Dilek Çağlayan , Şener Cihan, Yusuf Açikgöz , Doğan Uncu   +33 more
doaj   +1 more source

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

EBioMedicine, 2020
Background: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found ...
Xiaoyu Ding, Wanjian Gu, Yujie Zhong, Xiaoyao Hao, Jinyu Liu, Shukai Xia, Lan Luo, Mingjiu Chen, Chunni Zhang   +8 more
doaj   +1 more source

Resistance to Trastuzumab

Cancers, 2022
One of the most impactful biologics for the treatment of breast cancer is the humanized monoclonal antibody, trastuzumab, which specifically recognizes the HER2/neu (HER2) protein encoded by the ERBB2 gene. Useful for both advanced and early breast cancers, trastuzumab has multiple mechanisms of action.
Vivekanandhan, Sneha, Knutson, Keith L.
openaire   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

EJNMMI Radiopharmacy and Chemistry, 2023
Background Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain.
Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M. Reilly   +4 more
doaj   +1 more source

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

Frontiers in Pharmacology, 2023
Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a small
Huifang Lv, Yunduan He, Caiyun Nie, Feng Du, Xiaobing Chen   +4 more
doaj   +1 more source

Trastuzumab

Women's Health, 2005
Breast cancer is a heterogenous disease with several clinical and biologic subtypes. Human epidermal growth factor receptor 2 (HER 2) is overexpressed in approximately 20% of breast cancers. This overexpression is usually due to HER 2 gene amplification, and results in a more aggressive tumor with a worse prognosis.
Ian E, Smith, Susan G, Cross
openaire   +2 more sources

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Scientific Reports, 2021
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal ...
Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim   +3 more
doaj   +1 more source

Current perspective – Trastuzumab [PDF]

European Journal of Cancer, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Hall, P.S., Cameron, D.A.
openaire   +3 more sources

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source